In recent years, many studies have demonstrated that RSK2 plays a central role in the cell proliferation, metastasis and survival in various tumors and targeting it may improve the clinical efficiency of cancer therapies (Kang and Chen, 2011; Ma et al., 2018; Yoo et al., 2019). The gene discussed is RPS6KA3; the disease is cancer.